Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

NCT04337593 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma

Interventions

DRUG: Basiliximab
DRUG: Pegaspargase

Sponsor

Beijing Tongren Hospital